Cardiopulmonary coupling and serum cardiac biomarkers in obesity hypoventilation syndrome and obstructive sleep apnea with morbid obesity

Sheila Sivam, David Wang, Keith K. H. Wong, Amanda J. Piper, Yi Zhong Zheng, Gislaine Gauthier, Christine Hockings, Olivia McGuinness, Collette Menadue, Kerri Melehan, Sara Cooper, Hugi Hilmisson, Craig L. Phillips, Robert J. Thomas, Brendon J. Yee, Ronald R. Grunstein

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Study Objectives: The main cause of death in patients with obesity hypoventilation syndrome (OHS) is cardiac rather than respiratory failure. Here, we investigated autonomic-respiratory coupling and serum cardiac biomarkers in patients with OHS and obstructive sleep apnea (OSA) with comparable body mass index and apnea-hypopnea index.

Methods: Cardiopulmonary coupling (CPC) and cyclic variation of heart rate analysis was performed on the electrocardiogram signal from the overnight polysomnogram. Cardiac serum biomarkers were obtained in patients with OHS and OSA with a body mass index > 40 kg/m2. Samples were obtained at baseline and after 3 months of positive airway pressure (PAP) therapy in both groups.

Results: Patients with OHS (n = 15) and OSA (n = 36) were recruited. No group differences in CPC, cyclic variation of heart rate, and serum biomarkers were observed at baseline and after 3 months of PAP therapy. An improvement in several CPC metrics, including the sleep apnea index, unstable sleep (low-frequency coupling and elevated low-frequency coupling narrow band), and cyclic variation of heart rate were observed in both groups with PAP use. However, distinct differences in response characteristics were noted. Elevated low-frequency coupling narrow band coupling correlated with highly sensitive troponin-T (P < .05) in the combined cohort. Baseline highly sensitive troponin-T inversely correlated with awake oxygen saturation in the OHS group (P < .05).

Conclusions: PAP therapy can significantly improve CPC stability in patients with obesity with OSA or OHS, with key differences. Elevated low-frequency coupling narrow band may function as a surrogate biomarker for early subclinical cardiac disease. Low awake oxygen saturation could also increase this biomarker in OHS.

Clinical Trial Registration: Registry: Australian New Zealand Clinical Trials Registry; Name: Obesity Hypoventilation Syndrome and Neurocognitive Dysfunction; URL: https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=367492; Identifier: ACTRN12615000122550.

Original languageEnglish
Pages (from-to)1063-1071
Number of pages9
JournalJournal of Clinical Sleep Medicine
Volume18
Issue number4
DOIs
Publication statusPublished - 1 Apr 2022
Externally publishedYes

Keywords

  • Australia
  • Biomarkers
  • Humans
  • Obesity Hypoventilation Syndrome/complications
  • Obesity, Morbid/complications
  • Polysomnography
  • obstructive sleep apnea
  • cardiovascular disease
  • electrocardiogram
  • biomarker
  • obesity hypoventilation syndrome

Fingerprint

Dive into the research topics of 'Cardiopulmonary coupling and serum cardiac biomarkers in obesity hypoventilation syndrome and obstructive sleep apnea with morbid obesity'. Together they form a unique fingerprint.

Cite this